Viewing Study NCT06574620


Ignite Creation Date: 2025-12-25 @ 4:27 AM
Ignite Modification Date: 2025-12-26 @ 3:30 AM
Study NCT ID: NCT06574620
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-09-23
First Post: 2024-08-26
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
Sponsor: British Columbia Cancer Agency
Organization:

Study Overview

Official Title: Accelerating the Actionability of Treatment in Resected and Locally Advanced Pancreatic Cancer
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ACCELERATE
Brief Summary: The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:

* Is it feasible to obtain genetic test results within a timeframe that can help inform treatment decisions for individuals with PDAC?
* Can the genetic test results provide information about how a tumour will respond to or resist treatment?

Participants will:

* Receive standard chemotherapy to treat their cancer.
* Provide samples of their blood, tissue, and fluid for genetic testing.
* Visit the clinic every 4 weeks for check-ups and tests.
* Complete questionnaires every 12 weeks.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: